<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01403571</url>
  </required_header>
  <id_info>
    <org_study_id>2103038AJ</org_study_id>
    <nct_id>NCT01403571</nct_id>
  </id_info>
  <brief_title>Effectiveness and Safety of Salba on Weight Loss in Overweight Individuals With Type 2 Diabetes</brief_title>
  <acronym>LOSS</acronym>
  <official_title>Efficacy and Safety of Whole Grain Salba (Salvia Hispanica L.) on Weight Loss in Overweight and Obese Individuals With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Unity Health Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Diabetes Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Unity Health Toronto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Canadian statistics indicate that the incidence of obesity is increasing and that the&#xD;
      occurrence of diabetes in obese individuals is 5-fold greater than those with a healthy&#xD;
      weight, making weight control in this population particularly relevant. Preliminary clinical&#xD;
      data has shown that the whole grain, Salba, may improve type 2 diabetes control, reduce&#xD;
      after-meal blood glucose, cardiovascular disease (CVD) risk factors and suppress appetite.&#xD;
      Its use may therefore have potential implications in long-term weight management, while&#xD;
      improving diabetes.&#xD;
&#xD;
      The objective of this research (weight loss) is to evaluate whether adding Salba to an energy&#xD;
      reduced diet for six months will result in greater weight loss compared to control in&#xD;
      overweight and obese individuals with type 2 diabetes. The study recruited 77 overweight or&#xD;
      obese individuals with type 2 diabetes. They were instructed to follow a calorie restricted&#xD;
      diet and their regular diabetes therapy together with regular exercise. Participants were&#xD;
      randomly assigned to receive 30 g Salba/1000 kcal of daily energy requirements, or an oat&#xD;
      bran control supplement matched for energy. The effect of the supplements on weight-loss&#xD;
      (including waist circumference, % body fat) and glucose control (A1c, fasting glucose levels)&#xD;
      will be assessed. In addition, related outcomes such as low-grade body inflammation,&#xD;
      hunger-regulating hormones (ghrelin, adiponectin), safety measures (urea, creatinine, ALT and&#xD;
      prothrombin time) and satiety scores were evaluated.&#xD;
&#xD;
      Modest weight loss has been associated with improved glucose control in individuals with type&#xD;
      2 diabetes. Addition of Salba to an energy reduced diet may facilitate greater weight loss&#xD;
      and improve glycemic control and CVD risk factors compared to such a diet alone. Salba may&#xD;
      also promote maintenance of weight loss and therefore help prevent weight gain by providing&#xD;
      feelings of fullness that reduce appetite. In light of the high incidence of obesity in&#xD;
      individuals with diabetes, Salba grain may be a useful addition to the diet.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Weight</measure>
    <time_frame>24 weeks</time_frame>
    <description>24 week timeframe for Weightloss phase</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Body composition</measure>
    <time_frame>24 weeks</time_frame>
    <description>24 week timeframe for Weightloss phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood sugar control</measure>
    <time_frame>24 weeks</time_frame>
    <description>(HbA1c and Fasting glucose) 24 week timeframe for Weightloss phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Low grade body inflammation</measure>
    <time_frame>24 weeks</time_frame>
    <description>hs-CRP levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum ALT</measure>
    <time_frame>24 weeks</time_frame>
    <description>Safety Measures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prothrombin time</measure>
    <time_frame>24 weeks</time_frame>
    <description>Safety Measures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum creatinine</measure>
    <time_frame>24 weeks</time_frame>
    <description>Safety Measures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood urea</measure>
    <time_frame>24 weeks</time_frame>
    <description>Safety Measures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satiety hormones</measure>
    <time_frame>24 weeks</time_frame>
    <description>ghrelin, adiponectin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatty Acids (% composition)</measure>
    <time_frame>24 weeks</time_frame>
    <description>ALA (18:3 n-3), LA (18:2 n-6); Compliance measure</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">77</enrollment>
  <condition>Diabetes Mellitus</condition>
  <condition>Overweight</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Salba supplement</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30g/1000kal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oat-bran based Control Supplement</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>36g/1000kcal</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Salba (Salvia hispanica L.)</intervention_name>
    <description>30g/1000kcal/day over 24 wks</description>
    <arm_group_label>Salba supplement</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Oat-based Control</intervention_name>
    <description>Placebo: 36g/1000kcal/day over 24 weeks</description>
    <arm_group_label>Oat-bran based Control Supplement</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Well-controlled type 2 diabetes for at least 1 year&#xD;
&#xD;
          -  Treated with diet and/or oral hypoglycemic medications&#xD;
&#xD;
          -  BMI 25-40 kg/m2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Weight change in the past three months &gt;10% of body weight&#xD;
&#xD;
          -  On insulin therapy&#xD;
&#xD;
          -  Unstable angina, myocardial infarction or stroke (within 6 months)&#xD;
&#xD;
          -  Planned surgery or pregnancy&#xD;
&#xD;
          -  Blood pressure &gt;160mmHg/100mmHg&#xD;
&#xD;
          -  Surgical procedures for weight loss and concomitant use of medication or supplements&#xD;
             that alter body weight or appetite&#xD;
&#xD;
          -  ALA, dietary fibre, fish oil supplements or consuming cold-water fish more than three&#xD;
             times per week&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Risk Factor Modification Centre, St. Michael's</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <study_first_submitted>July 25, 2011</study_first_submitted>
  <study_first_submitted_qc>July 25, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 27, 2011</study_first_posted>
  <last_update_submitted>October 4, 2016</last_update_submitted>
  <last_update_submitted_qc>October 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Overweight</mesh_term>
    <mesh_term>Weight Loss</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

